期刊文献+

西那卡塞对血液透析患者继发性甲状旁腺功能亢进的临床治疗 被引量:3

Clinical Effect of Si Bernard Casey in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
下载PDF
导出
摘要 目的探究对持续性血液透析患者继发性甲状旁腺功能亢进(SHPT)病例采用西那卡塞进行治疗的临床效果。方法选择本院收治的维持性血液透析并发SHPT的患者18例服用盐酸西那卡塞进行治疗,治疗中定期测定患者血钙值并以此为依据调整西那卡塞的用药量,治疗持续8周。观察并记录患者治疗前后患者各临床指标及症状。结果所有患者在治疗结束后,全段甲状旁腺激素(i PTH)、血钙、血磷、碱性磷酸酶(ALP)以及血钙磷乘积都较治疗前有显著的降低,差异有统计学意义(P<0.05)。此外患者的四肢无力以及皮肤瘙痒等临床症状均得到一定程度的缓解。结论对血液透析并SHPT患者采用西那卡塞来治疗,能够降低患者的i PTH,ALP,血钙,血磷等水平并改善患者的各临床症状。 Objective To explore the hyperthyroidism sustained hemodialysis patients with secondary hyperparathyroidism (SHPT) were treated with cinacalcet the clinical effects of treatment. Methods 18 cases with SHPT taking cinacalcet hydrochloride for treatment were chosen to maintain in our hospitalhemodialysis,determination of serum calcium in the treatment of regular value was detected and as adjusted the dosage according to Si Bernard Casey, the treatment lasted for 8 weeks. The clinical symptoms and symptoms of patients before and after treatment were observed and recorded. Results All the patients after treatment, intact parathyroid hormone (iPTH), serum calcium, phosphorus, alkaline phosphatase (ALP) and the product of calcium and phosphorus were significantly decreased, the difference was significant (P〈0.05), In addition, patients with limb weakness and skin itching and other clinical symptoms were alleviated to some extent. Conclusion The blood dialysis patients with SHPT Xinaka celecoxib treatment, patients can reduce the iPTH, ALP, blood calcium, blood phosphorus level and improve the clinical symptoms of the patients.
作者 武仁 王晶
出处 《中国继续医学教育》 2017年第7期165-167,共3页 China Continuing Medical Education
关键词 西那卡塞 血液透析 继发性甲状旁腺功能亢进 疗效 Si Bernard Casey hemodialysis secondary hyperparathyroidism curative effect
  • 相关文献

参考文献8

二级参考文献67

  • 1燕宇.西那卡塞的临床应用以及研究进展[J].中国血液净化,2012,11(8):460-463. 被引量:23
  • 2Brown EM, Gamba G, Riccardi D, et al. Chining and characterization of an extracellular Ca (2+)-sensing receptor from bovine parathyroid. Nature, 1993,366:575-580.
  • 3Nagano N, Nemeth EF. Functional proteins involved in regulation of intracellular Ca (2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci.2005.97:355-360.
  • 4Bahner U, Brandl M, Nies C, et al. Use of cinacalcet HC1 to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism. J Ren Nu- tr,2008,18: 383-388.
  • 5Borchhardt KA, Diarra D, Sulzbacher I, et al. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol,2010,31:482-489.
  • 6Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Trans,2009,24:982-989.
  • 7Caudrillier A, Mentaverri R, Brazier M, et al. Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease. J Nephrol,2010,23:17-22.
  • 8Dillon ML, Frazee LA. Cinacalcet for the treatment of primary hyperparathyroidism. Am J Ther,2010,.
  • 9Brown EM,Gamba G,Riccardi D, et al. Cloning and characteriza- tion of an extraceltular Caz+Ssensing receptor from bovine para- thyroid[J]. Nature , 1993,366 : 575.
  • 10Smajilovie S, Tfelt-Hansen J. Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system [J]. Cardiovascular research,2007,75(3) :457.

共引文献67

同被引文献14

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部